Oncolytics reports positive initial preclinical data for pelareorep + RAS inhibitors; further studies planned

ONCOLYTICS BIOTECH INC

Initial data in solid tumor model shows greater anti-tumor activity with pelareorep+RAS inhibitor vs either alone.
Company planning additional studies in pancreatic ductal adenocarcinoma (PDAC) and colorectal cancer (CRC) models.
Evaluating combinations with KRAS G12C inhibitors, pan-RAS inhibitors, and next-generation RAS-targeted agents.
Full dataset expected to be presented in fall/winter 2026.
CEO states belief that pelareorep may serve as immune-priming backbone for next-generation targeted therapies.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.